Brooklyn Immunotherapeutics Inc
Change company Symbol lookup
Select an option...
BTX Brooklyn Immunotherapeutics Inc
SBCF Seacoast Banking Corporation of Florida
MSSAU Metal Sky Star Acquisition Corp
SDGR Schrodinger Inc
GPC Genuine Parts Co
VENA Venus Acquisition Corp
VECO Veeco Instruments Inc
IGTAU Inception Growth Acquisition Ltd
BAC-K Bank of America Corp
FAX abrdn Asia-Pacific Income Fund Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Health Care : Biotechnology |
Company profile

Brooklyn ImmunoTherapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cytokine-based therapies for treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its lead product candidate, IRX-2, is a cytokine therapy, to treat patients with head and neck cancer. IRX-2 is a mixed, human-derived cytokine product with multiple active constituents including Interleukin-2 (IL2) and other key cytokines, which restore immune function suppressed by the tumor, thus enabling the immune system to attack cancer cells. The Company also has multiple cell and gene-editing therapies in preclinical development for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as in vivo gene-editing therapies for rare genetic diseases. Its subsidiaries include Brooklyn ImmunoTherapeutics LLC, Novellus, Inc. and Novellus Therapeutics, Ltd.

Closing Price
$0.2303
Day's Change
-0.0319 (-12.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.2993
Day's Low
0.2303
Volume
(Heavy Day)
Volume:
1,727,500

10-day average volume:
815,612
1,727,500

DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in First High-School Education Group Co., Ltd. with Losses of $100,000 to Contact the Firm

8:38 am ET July 8, 2022 (Newsfile) Print

Los Angeles, California--(Newsfile Corp. - July 8, 2022) - The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against First High-School Education Group Co., Ltd. ("First High-School Education Group" or "the Company") (NYSE: FHS) for violations of the federal securities laws.

Investors who purchased the Company's shares pursuant and/or traceable to the Company's initial public offering conducted in March 2021 (the "IPO") are encouraged to contact the firm before July 11, 2022.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. First High-School Education Group misrepresented the material adverse threat to its business posed by the Chinese government's new rules, regulations, and policies. The Government's proposed rules on private education were already impacting the Company through a slowdown in approvals for new facilities. Based on these facts, the Company's public statements and documents released throughout the IPO period were false and materially misleading. When the market learned the truth about First High-School Education Group, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm

Brian Schall, Esq.,

www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/130340

comtex tracking

COMTEX_409859180/2523/2022-07-08T08:38:34

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.